In 1990 study in San Diego, CA the 5 active subjects with allergic rhinitis had a lowered total serum IgE from Day 0 to Day 90 while 4 placebo subjects, products and for (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat or increased IgE levels.4 In a randomized, double-blind, placebo controlled study of symptoms and serum nose IgE levels in San Diego, CA in mid-1991, subjects had allergic rhinitis and/or asthma. Serum was drawn at Day 0 and bleeds and products Day 30. Seven of the 10 active treated for subjects had a reduction in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total serum IgE that stayed the same (plus or minus 5%), 3 decreased and 2 increased.5 Statistical analysis of the open-label study as nose well as the double-blind randomized placebo controlled study have shown a significant effect of vitamin B12 in lowering serum IgE concentrations.

In bleeds 1992 in El Paso, TX a randomized, double-blind, placebo controlled products study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced for and nose significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days bleeds 365 to 395 (the same products period, one year after the for first nose set of symptom diaries). bleeds The active group had mean symptom products scores showing statistically significant for decreases nose and bleeds from 1992 products to 1993. The placebo group had increased symptoms in 1993. for (The relevant pollen counts at the study site in nose 1993 were bleeds and products much higher for than in 1992, leading to expectation of higher nose and bleeds symptoms.)7